Unlock your financial potential trading stocks!
May 21, 2019 by Sultan Beardsley
May 20, 2019 by Chris Stang
May 20, 2019 by Sultan Beardsley
The past week of trading was a mixed bag. On Monday we saw what I would call a "flash crash". The DJI dropped over 600 points in the morning (-2.4%) and proceeded to have its worst day this year since … [Read More...] about Biopharma Stock Watch May 20th-24th
In my previous article "Investing In This Biotech Sector Could Triple Your Net Wealth In 2-Years" I laid out my rationale for investing in NAFLD/NASH companies. I reasoned that by investing in … [Read More...] about An Attractive Biotech Stock Gunning For NASH
Amarin (AMRN) submitted its supplemental new drug application (sNDA) for Vascepa on March 28th. Given the FDA review timeline, there are upcoming catalysts for this filing that could weigh heavily on … [Read More...] about INVESTOR ALERT: Why Amarin May Already Know Their Chances of Receiving Priority Review
Background Endra Life Sciences (NDRA) is a clinical stage medical device company we started following in April, 2019. The share price galloped up to a high near $3.30 in March in anticipation of … [Read More...] about Investor Alert: Endra Life Scienes (NDRA)
Recently tech companies have been eager to go public and unload shares from the insiders to the less knowledgeable retail. Some have been successful, some have not. Zoom has seen success in their IPO … [Read More...] about Will Uber Make You Money In The Stock Market?
Novartis' PDUFA date is May 2019While approval may not have a significant impact on Novartis' price, a patterns suggests there may be money to be made on Ionis' stock The time is drawing nearer to … [Read More...] about PDUFA Watch: Novartis’ Zolgensma (AVXS-101)
*90% Of Traders
Lose Money
*100% DON'T
Have To
At MS Money Moves we leverage our teams expertise in science, business, and technical analysis identifying gainful biotech trades.
How we do it?
Patience, Discipline, Objective Analysis.
See our performance record for more info.
Try it for free, Let's get it!
